CClinicalTrials.gg
Not yet recruitingNCT07847814Updated Sep 29, 2026

Evaluation of F&P Mask, US, 2026

An interventional study of F&P Mask in Chronic Respiratory Conditions and Obstructive Sleep Apnea (OSA), sponsored by Fisher and Paykel Healthcare. Not yet recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

This clinical investigation is designed to validate and confirm the overall performance, safety, usability, reliability, and acceptability of the F\&P mask in a home environment.

02

Conditions studied

  • Chronic Respiratory Conditions
  • Obstructive Sleep Apnea (OSA)
03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Are ≥22 years of age
  • Weigh ≥66 pounds
  • Have been prescribed PAP/NIV therapy by a physician
  • Are an existing PAPNIV mask user with ≥3 months of use prior to enrolment in the clinical investigation
  • Are compliant with PAP/NIV therapy for ≥4 hours per night for ≥70% of nights for a 14-day period within 30 days prior to enrolment in the clinical investigation
  • Are fluent in spoken and written English
  • Possess the capacity to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Possess, or suffer from, anatomical or physiological conditions which make PAP/NIV therapy inappropriate
  • Are required to use PAP/NIV therapy for >12 hours per day or for extensive periods, not including sleep or naps
  • Are trying to get pregnant, are pregnant, or think they may be pregnant
  • Have an IPAP pressure of >30 cmH2O if on BPAP
  • Use a PAP/NIV therapy device for the delivery of medicines, except supplemental O2
  • Use a PAP/NIV therapy device that does not possess data recording capabilities to capture AHI and a numerical indicator of leak that is accessible to the clinical investigation site
  • Have a history of light-induced seizures (for optional anthropometric scan only)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Other
    Intervention

    Single-arm, non-randomised, open-label

    Device: F&P Mask

Interventions

  • DeviceF&P Mask

    PAP/NIV Therapy Mask

05

What researchers measure

Primary outcomes

  1. Therapeutic Efficacy

    Determined by Apnea-Hypopnea Index (AHI) recorded on PAP therapy machines after 14 days of use. The Apnea-Hypopnea index (AHI) is the sum of the apneas and hypopneas divided by the hours of sleep. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and \>= 30/h = severe AHI is measured by dividing the total number of recorded apneas (complete breathing stops) and hypopneas (shallow breathing episodes) by the total number of hours a person slept during an overnight sleep study or using a PAP device. Higher AHI values represent worse outcomes. There is no maximum theoretical index score.

    Time frame: Baseline and 14±5 days

  2. Epworth Sleepiness Scale

    All relevant time points used in the calculation in the Time Frame (e.g., baseline and 14±5 days). Note: change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 14±5 days minus value at baseline). Change between two time points is reported. Scale range: 0 (minimum score) to 24 (maximum score) (higher scores represent worse outcomes)

    Time frame: 14±5 days

  3. Patient and Clinical Global Impression (PGI/CGI)

    Determined by Patient Global Impression (PGI) and Clinical Global Impression (CGI) assessments completed at baseline and Day 14. Baseline symptom severity is assessed using a 6-point scale (1 = No symptoms to 6 = Very severe symptoms). Change from baseline is assessed using a 7-point scale (1 = Very much better to 7 = Very much worse; 4 = No change). Higher severity scores indicate worse symptoms. For change assessments, lower scores indicate improvement and higher scores indicate worsening. PGI is completed by the patient and CGI is completed by the investigator/clinician.

    Time frame: Baseline and 14±5 days

06

Study locations

1 site
  • Bogan Sleep Consultants
    Columbia, South Carolina 29201, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07847814
Lead sponsor
Fisher and Paykel Healthcare
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
May 14, 2027 (estimated)
Completion
Jul 14, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Subbarao Potharaju
Contact
Subbarao.Potharaju@fphcare.com
+1 800-792-3912

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion